Public Area
MabThera International Trial - MInT
Homepage
Introduction
Randomised Intergroup Trial of First Line Treatment for Patients with Diffuse Large B-Cell Lymphoma with a CHOP-Like Chemotherapy Regimen with or without the CD20 antibody Rituximab (MabThera, IDEC-C2B8).Patient information
If your are willing to participate in this clinical trial please contact your local physician for further advice.Organisational structure
Steering committee:
- Principal Investigator: M. Pfreundschuh, Homburg Germany
- Sponsor: Hoffmann-La Roche AG, M. Rashford, Basel Switzerland
- Co-ordinating Statistician: M. Loeffler, Leipzig Germany